Skip to content

The efficacy and safety of Jingfang Granules in treating air-conditioning diseases

The efficacy and safety of Jingfang Granules in treating air-conditioning diseases: a prospective, single center, open, randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003664
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-08-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Disease of Air Conditioning

Interventions

Sponsors

Zhangjiagang Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The subject must meet all of the following criteria at the same time: (1) Male or female between 18 and 70 years old; (2) The experience of being exposed to an air-conditioned environment or frequently entering and leaving air-conditioned rooms on hot days (June to October) and at least 3 days before the onset; (3) Meet the diagnostic criteria of Western medicine for the common cold (edited by Chen Haozhu. Practical Internal Medicine. 10th edition. People's Medical Publishing House); (4) Comply with the diagnostic criteria of TCM syndromes for wind-cold cold [Guidelines for TCM Diagnosis and Treatment of Common Colds (2015 Edition)]; (5) Within 48 hours of onset; (6) Those who have not taken Jingfang Granules, Xinkangtai Ke (blue), Tylenol cold tablets, Xinkang Taike (red), Day and Night Baifuzhu (night tablets), etc. within 2 weeks before enrollment; (7) Subjects voluntarily joined the study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: Exclude subjects who meet any of the following criteria: (1) Diseases accompanied by pharyngeal conjunctivitis, acute exacerbation of chronic bronchitis, purulent tonsillitis, and infectious upper respiratory tract infection; (2) People with uncontrolled cardiovascular and cerebrovascular diseases, diabetes, hypertension, thyroid disease, asthma, glaucoma, emphysema, chronic lung diseases, breathing difficulties or prostatic hypertrophy; (3) Patients with pneumonia confirmed by chest imaging; (4) Those who have used drugs to treat the disease after the onset of illness; (5) Those who are currently taking nourishing proprietary Chinese medicines or monoamine oxidase inhibitors; (6) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 3 times the upper limit of normal value or active liver disease; (7) Serum creatinine> 2 times the upper limit of normal or undergoing renal dialysis treatment; (8) Axillary temperature >= 40 degrees C, total number of white blood cells>10x109/L or neutrophil classification>80%; (9) Those who are allergic to the drugs used in this research; (10) Mental and neurological disorders, who cannot express their wishes correctly; (11) Pregnant women, lactating women and women of childbearing age who have not taken contraceptive measures; (12) Those who are currently participating in clinical trials of other drugs or medical devices; (13) The investigator believes that it is not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Recovery rate on the 3rd day of treatment;

Countries

China

Contacts

Public ContactLi Yuqing
183567028@qq.com+86 13962255449

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026